HALO Halozyme Therapeutics Inc.

16.28
+0.43  (+3%)
Previous Close 15.85
Open 15.96
Price To Book 9.15
Market Cap 2,381,941,778
Shares 146,310,920
Volume 981,232
Short Ratio
Av. Daily Volume 882,115

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 initiation announced October 31, 2017.
DARZALEX (Daratumumab) using ENHANZE
Amyloidosis
Primary endpoint was met March 2, 2017. Data released June 5, 2017 - HR 0.81. Disease-free-survival +0.9% over Herceptin.
Perjeta + Herceptin (APHINITY)
Adjuvant HER2+ breast cancer
Approval announced June 22, 2017.
Subcutaneous rituximab
Various blood cancers
Discontinued August 2016
PEGPH20 in Combination with docetaxel
Non-small cell lung cancer (NSCLC)
Phase 3 data due by December 2019.
HALO-301
Pancreatic cancer
Approved September 12, 2014.
HYQVIA
Subcutaneous treatment for patients with primary immunodeficiency (PI)
Phase 3 trial initiation announced July 26, 2018.
Subcutaneous Pertuzumab And Trastuzumab
HER2-positive early breast cancer
Phase 1b trial ongoing. 42/70 patients have enrolled as of December 2018.
PEGPH20 and atezolizumab
Cholangiocarcinoma
Phase 1b/2 data due late 2019 or early 2020.
BL-8040 in combination with TECENTRIQ (atezolizumab) and PEGPH20
Pancreatic cancer
FDA approval announced February 28, 2019.
Trastuzumab (Herceptin) using ENHANZE
Breast cancer
sBLA filing announced July 12, 2019. PDUFA estimate May 12, 2020.
DARZALEX (Daratumumab) using ENHANZE
Multiple myeloma
Phase 1 trial to commence 1Q 2020.
ARGX-117
Autoimmune diseases
Phase 1 data due YE 2019.
Efgartigimod (ARGX-113) and Enhanze

Latest News

  1. Edited Transcript of HALO earnings conference call or presentation 6-Aug-19 8:30pm GMT
  2. Halozyme Therapeutics Inc (HALO) Q2 2019 Earnings Call Transcript
  3. Halozyme Therapeutics (HALO) Reports Q2 Loss, Lags Revenue Estimates
  4. Halozyme Reports Second Quarter 2019 Results
  5. Is Halozyme Therapeutics (NASDAQ:HALO) Weighed On By Its Debt Load?
  6. Earnings Preview: Halozyme Therapeutics (HALO) Q2 Earnings Expected to Decline
  7. Halozyme To Participate In 39th Annual Canaccord Genuity Growth Conference
  8. Halozyme To Host Second Quarter 2019 Financial Results Webcast And Conference Call
  9. Alexion (ALXN) to Report Q2 Earnings: What's in the Cards?
  10. Halozyme Announces Janssen Submits Extension Application To European Medicines Agency For Subcutaneous Formulation Of DARZALEX® Utilizing ENHANZE® Technology
  11. Halozyme Announces First Clinical Dosing In argenx's Phase 1 Trial Of Efgartigimod (ARGX-113) With ENHANZE® Drug Delivery Technology
  12. Halozyme Announces Janssen Submits BLA To FDA For Subcutaneous Formulation Of DARZALEX® Utilizing ENHANZE® Technology
  13. The Halozyme Therapeutics (NASDAQ:HALO) Share Price Has Gained 99% And Shareholders Are Hoping For More
  14. Halozyme Announces CRADA With National Institute of Allergy and Infectious Diseases For Use Of ENHANZE® Drug Delivery Technology
  15. See what the IHS Markit Score report has to say about Halozyme Therapeutics Inc.
  16. Edited Transcript of HALO earnings conference call or presentation 7-May-19 8:30pm GMT
  17. Is Halozyme Therapeutics, Inc. (HALO) A Good Stock To Buy?
  18. Halozyme To Participate In Upcoming Investor Conferences
  19. Is Halozyme Therapeutics, Inc.'s (NASDAQ:HALO) Balance Sheet Strong Enough To Weather A Storm?
  20. Halozyme Announces argenx Has Selected Second Target Under ENHANZE® Technology Collaboration And License Agreement